Parexel launches dedicated biotech division

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/Pattanaphong Khuankaew)
(Image: Getty/Pattanaphong Khuankaew)

Related tags: Parexel, Parexel Biotech

Parexel Biotech will support emerging companies from development through commercialization with tailored services and customized guidance, says division lead.

The division – Parexel Biotech – offers a new biotech-focused team and organizational structure for customers, and will be led by James Anthony, global head of biotech, and Graciela Racaro, global head of biotech operations.

“Parexel understands that emerging biotech companies have different needs and require a different style of service than large, established pharmaceutical companies, and will be able to provide these companies with tailored, customized guidance to meet those specific needs,”​ Anthony told Outsourcing-Pharma.

The contract research organization (CRO) has worked with biotech companies for several years, but the new division now provides a dedicated team focused on the needs of emerging companies, he added.

“Emerging biotech customers serve as the innovative arm of the industry, driving new therapies forward for development with the ultimate goal of market approval,” ​said Anthony – and the CRO's percentage of its overall business sponsored by this market segment has grown significantly over the past decade.

Parexel Biotech’s offering will include regulatory and strategic consulting, the ability to recruit patients and conduct trials, generation of real-world evidence (RWE) leveraging internal expertise and partnerships, such as with Datavant and SHYFT Analytics, among others.

Related news

Show more

Related products

show more

dPCR Case Study

dPCR Case Study

CellCarta | 08-Aug-2022 | Case Study

Streamline your adoptive cell therapy program with digital PCR. Our team has a unique expertise in digital and quantitative PCR to support you in ensuring...

Standardizing data with NCI controlled terminology

Standardizing data with NCI controlled terminology

Formedix | 18-Jul-2022 | Technical / White Paper

The use of consistent terminology within and between studies is critical to enabling an efficient trial process. CDISC standards such as CDASH, SDTM, SEND...

Planning Your First-In-Human Trial

Planning Your First-In-Human Trial

Altasciences | 15-Jul-2022 | Technical / White Paper

A first-in-human (FIH) clinical trial is a significant milestone in the development of a potential new drug. A successfully conducted FIH trial provides...

Seasonal Vaccine Manufacturing

Seasonal Vaccine Manufacturing

Baxter BioPharma Solutions | 13-Jul-2022 | Technical / White Paper

The production of seasonal vaccines, such as those for influenza, presents unique challenges to manufacturers due to the necessary time constraints resulting...

Related suppliers

Follow us

Products

View more

Webinars